About CytoReason
CytoReason is a company based in Haifa (Israel) founded in 2016.. CytoReason has raised $100 million across 3 funding rounds from investors including Thermo Fisher Scientific, Nvidia and OurCrowd. CytoReason offers products and services including Disease Model and Drug Portfolio Manager. CytoReason operates in a competitive market with competitors including Insitro, HotSpot Therapeutics, TOLREMO therapeutics, Certara and Inpharmatica, among others.
- Headquarter Haifa, Israel
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Cytoreason Ltd
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$100 M (USD)
in 3 rounds
-
Latest Funding Round
$80 M (USD), Series C
Jul 17, 2024
-
Investors
Thermo Fisher Scientific
& 4 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of CytoReason
CytoReason offers a comprehensive portfolio of products and services, including Disease Model and Drug Portfolio Manager. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
AI tool for modeling diseases and comparing treatments.
Platform to prioritize and compare drug programs across populations.
Unlock access to complete
Unlock access to complete
Funding Insights of CytoReason
CytoReason has successfully raised a total of $100M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $80 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series C — $80.0M
-
First Round
First Round
(22 Sep 2022)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2024 | Amount | Debt – Conventional - CytoReason | Valuation |
investors |
|
| Jul, 2024 | Amount | Series C - CytoReason | Valuation | OurCrowd , NVIDIA |
|
| Sep, 2022 | Amount | Series B - CytoReason | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in CytoReason
CytoReason has secured backing from 5 investors, including institutional investors. Prominent investors backing the company include Thermo Fisher Scientific, Nvidia and OurCrowd. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Pharmaceutical products for treating multiple diseases are provided.
|
Founded Year | Domain | Location | |
|
Secondary fund investments are emphasized by this Israeli commercial bank.
|
Founded Year | Domain | Location | |
|
Network connecting investors to startups, venture capital funds, and alternatives
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by CytoReason
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - CytoReason
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cytoreason Comparisons
Competitors of CytoReason
CytoReason operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, HotSpot Therapeutics, TOLREMO therapeutics, Certara and Inpharmatica, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Developer of a platform for protein function analysis
|
|
| domain | founded_year | HQ Location |
Anti-cancer small molecules are developed to target drug resistance pathways.
|
|
| domain | founded_year | HQ Location |
Provider of a platform for in silico drug discovery and consulting services
|
|
| domain | founded_year | HQ Location |
Developer of predictive informatics based platform for drug discovery
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Cytoreason
Frequently Asked Questions about CytoReason
When was CytoReason founded?
CytoReason was founded in 2016 and raised its 1st funding round 6 years after it was founded.
Where is CytoReason located?
CytoReason is headquartered in Haifa, Israel. It is registered at Haifa, Haifa District, Israel.
Is CytoReason a funded company?
CytoReason is a funded company, having raised a total of $100M across 3 funding rounds to date. The company's 1st funding round was a Series B of $20M, raised on Sep 22, 2022.
What does CytoReason do?
CytoReason was founded in 2016 in Haifa, Israel, within the biotechnology sector. Immune system-based drugs are developed through a proprietary platform that integrates scientific and experimental data. The immune system is stimulated and analyzed using high-resolution patient data alongside scientific research to support drug discovery processes. Operations focus on biological data analytics for therapeutic advancements.
Who are the top competitors of CytoReason?
CytoReason's top competitors include Insitro, HotSpot Therapeutics and Certara.
What products or services does CytoReason offer?
CytoReason offers Disease Model and Drug Portfolio Manager.
Who are CytoReason's investors?
CytoReason has 5 investors. Key investors include Thermo Fisher Scientific, Nvidia, OurCrowd, Pfizer, and Bank Hapoalim.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.